Antimicrobial Resistance among Campylobacter Strains, United States, 1997–2001
Amita Gupta* , Jennifer M. Nelson*, Timothy J. Barrett*, Robert V. Tauxe*, Shannon P. Rossiter*, Cindy R. Friedman*, Kevin W. Joyce*, Kirk E. Smith†, Timothy F. Jones‡, Marguerit A. Hawkins§, Beletshachew Shiferaw¶, James L. Beebe#, Duc J. Vugia**, Terry Rabatsky-Ehr††, James A. Benson‡‡, Timothy P. Root§§, Frederick J. Angulo*, and for the NARMS Working Group
Author affiliations: *Centers for Disease Control, Atlanta, Georgia, USA; †Minnesota Department of Health, St. Paul, Minnesota, USA; ‡Tennessee Department of Health, Nashville, Tennessee, USA; §Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA; ¶Oregon Department of Human Services, Portland, Oregon, USA; #Colorado Department of Public Health & Environment, Denver, Colorado, USA; **California Department of Health Services, Sacramento, California, USA; ††Connecticut Department of Public Health, Hartford, Connecticut, USA; ‡‡Georgia Department of Human Services, Atlanta, Georgia, USA; §§New York State Department of Health, Albany, New York, USA
Figure 1. Distribution of ciprofloxacin MICs among Campylobacter jejuni isolated from humans and retail chicken. A, human isolates, 1997–2001; n = 1,471. B, grocery store purchased chicken isolates, 1999; N = 62.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.